This study was planned to show the beneficial effects of prostacyclin (PGI2) on pulmonary function after heparin reversal with protamine. Twenty-eight patients entered the study. Half of these patients received prostacyclin, whereas the other patients did not.
N-acetyl glucosaminidase (NAG) level was 37.6 ± 4.7 pmoL/mL in the con trol group and 19.7 ± 3.8 pmoL/mL in the PGI2 group (p < 0.001) five minutes after protamine administration. Leukotriene B 4 (LTB4) level was 118 ±13.7 pmoL/mL in the control group and 56 ± 13.8 pmoL/mL in the PGI2 group (p < 0.001). Alveolar-arterial oxygen difference was 69± 15 mmHg in the con trol group and 58 ± 11 mmHg in the PGI2 group (p < 0.05).
As a result of this study it was concluded that PGI2 reduced the toxic mani festations of heparin-protamine complex and improved the pulmonary gas ex change.
Get full access to this article
View all access options for this article.
References
1.
Kirklin JK, Chenoweth DE, Naftel DC, et al: Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg41:193-199, 1986.
2.
Cavarochi NC , Schaff HV, Orszulak TA, et al: Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass. Surgery98:525-530, 1985.
3.
Morel DR, Zapol WM, Thomas SJ, et al: C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology66:597-604, 1987.
4.
Morel DR, Costabella PM, Pittet JF: Adverse cardiopulmonary effects and increased plasma thromboxane concentrations following the neutralization of heparin with protamine in awake sheep are infusion rate-dependent. Anesthesiology73:415-424, 1990.
5.
Fernandez HN , Henson AO, Hugli TE: Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and undersimulated in vivo conditions. J Immunol120:109-115, 1978.
6.
Webster RO, Hong SR, Johnston RB, et al: Biological effects of the human complement fragments C5a and C5a des Arg on neutrophil function. Immunopharmacology2:201-209, 1980.
7.
Maggart M., Stewart S.: The mechanisms and management of noncardiogenic pulmonary edema following cardiopulmonary bypass. Ann Thorac Surg43:231-236, 1987.
8.
Rent R., Ertel N., Eisenstein R., et al: Complement activation by interaction of polyanions and polycations. I. Heparin-protamine-induced consumption of complement. J Immunol114:120-124, 1975.
9.
Kreil E., Montalescot G., Greene E., et al: Nafamstat mesilate attenuates pulmonary hypertension in heparin-protamine reactions. J Appl Physiol67:1463-1471, 1989.
10.
Morel DR, Lowenstein E., Nguyenduy T., et al: Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep; evidence for the role of reactive oxygen metabolites following nonimmunological classical pathway complement activation. Circ Res62:905-916, 1988.
11.
McMurtry IF , Morris KG: Platelet-activating factor causes pulmonary vasodilation in the rat. Am Rev Respir Dis134:757-762, 1986.
12.
Tuszynski GP , Knight L., Piperno JR, et al: A rapid method for removal of 125I iodide following iodination of protein solutions . Anal Biochem106:118-122, 1980.
Grigorian GY , Ryan US: Platelet-activating factor effects on bovine pulmonary artery endothelial cells. Circ Res61:389-395, 1987.
15.
Baird BR, Cheronis JC, Sandhaus RA, et al: Oxygen metabolite and neutrophil elastase synergistically cause edematous injury in isolated rat lungs. J Appl Physiol61:2224-2229, 1986.
16.
Burghuber O. , Mathias MM, McMurtry IF, et al: Lung edema due to hydrogen peroxide is independent of cyclooxgenase products. J Appl Physiol56:900-905, 1984.
17.
Weishaar RE , Burrows SD, Kobylarz DC, et al: Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets . Biochem Pharmacol35:787-800, 1986.
18.
Sakai A., Chang S., Voelkel NF: Importance of vasoconstriction in lipid mediator-induced pulmonary edema. J Appl Physiol66:2667-2674, 1989 .
19.
Stelzner TJ , Weil JV, O'Brien RF: Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J Cell Physiol139:157-166, 1989.
